PO.MCB08.04 · 分子与细胞生物学

A large-scale sequencing study identifies a novel non-coding structural variant as a high-penetrance susceptibility variant for melanoma

编号 5939 展板 27 时间 4/21 02:00–05:00 区域 Section 21 主讲 Linh Bui-Raborn, PhD
分会场 Genetic and Transcriptomic Dissection of Cancer Evolution
该海报暂无可访问的完整资料 AACR 官方页面 ↗

作者与单位

Linh T. Bui-Raborn1, Lorenza Pastorino2, Donato Calista3, Huu Phuc Hoang1, Bruna Dalmasso4, Jessica Scales1, Sophie Papiernik1, Xiaoyu Wang1, Rohit Thakur1, Stefania Pellegrini5, Mai Xu1, Joshuah Yon1, William Bruno2, Tongwu Zhang1, Zaida García-Casado6, Enrica Teresa Tanda7, Francesco Spagnolo8, Monia Di Prete9, Irene Bottillo10, Siranoush Manukian11, Maria Chiara Scaini5, Katerina P. Kypreou12, Lucia Di Nardo13, Miriam Potrony14, Paula Aguilera-Peiró15, Nesreen Shahrour1, Tam-Anh Tran1, Weiyin Zhou1, Wen Lou1, Aurélie L. Vogt1, Jia Liu1, Kristine Jones1, Monica Rodolfo16, Irene Stefanaki12, Cristina Pellegrini17, Carlo Cota9, Chiara Menin5, Maria Concetta Fargnoli9, Ketty Peris18, Susana Puig14, Eduardo Nagore19, Paola Grammatico20, The Melanostrum Consortium, Jianxin Shi1, Paola Ghiorzo2, Kevin M. Brown1, Maria Teresa Landi1

1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD,2Department of Internal Medicine and Medical Specialties, University of Genoa; IRCCS Ospedale Policlinico San Martino, Genoa, Italy,3Department of Dermatology, Maurizio Bufalini Hospital, Cesena, Italy,4IRCCS Ospedale Policlinico San Martino, Genoa, Italy,5Immunology and Molecular Oncology Unit, Veneto Institute of Oncology (IOV-IRCCS), Padua, Italy,6Laboratory of Molecular Biology, Instituto Valenciano de Oncología, València, Spain,7Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy,8Medical Oncology 2, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy,9Dermatopathology Research Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy,10Laboratory of Medical Genetics, Experimental Medicine Department, San Camillo-Forlanini Hospital, Sapienza University, Rome, Italy,11Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy,121st University Clinic of Dermatological and Venereal Diseases, Andreas Syggros Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece,13Immunology Research Core Facility - Gemelli Science and Technology Park (GSTeP), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy,14Biochemistry and Molecular Genetics Department, Hospital Clínic of Barcelona, IDIBAPS, Barcelona, Spain,15Dermatology, Hospital Clínic de Barcelona, Barcelona, Spain,16Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy,17Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy,18Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy,19Dermatology, Instituto Valenciano de Oncología, València, Spain,20Experimental Medicine Department, Laboratory of Medical Genetics, Sapienza University of Rome, San Camillo-Forlanini Hospital, Rome, Italy

摘要 Abstract

Approximately 10% of cutaneous malignant melanoma cases are familial. Variants in CDKN2A account for ~40% of melanoma-prone families, with 10% more explained by other established genes. Strikingly, many unexplained families nonetheless show genetic linkage to chromosomal band 9p21, which harbors CDKN2A , suggesting that high-penetrance non-coding variants in the region may contribute to familial risk.As a part of a large-scale study of high-risk melanoma families from the Mediterranean region, we conducted germline whole-genome sequencing (WGS) on a melanoma case from a four-case family from Genoa, Italy, that is negative for variation in known susceptibility genes. We identified a novel 100kb deletion mapping to 9p21 205kb from CDKN2A and verified cosegregation in the two other available cases. The deletion is not protein-coding but contains annotated melanocyte enhancer elements and open chromatin that we find to interact with the promoters of the p16 and p14 transcripts of CDKN2A in melanocytes using H3K27Ac Hi-ChIP.To identify additional deletion carriers in whole-exome sequencing (WES) data, we searched for nearby exonic variants that cosegregate in the discovery family to serve as a proxy of the deletion, identifying a rare cosegregating missense variant in MTAP (rs755147810; chr9: 21,802,755:T:G; p.Ser3Ala; gnomADv4.1 Non-Finish European MAF: 3.4x10 -6 ). We assessed this variant in WES data from 3,574 high-risk Mediterranean melanoma patients and 2,673 controls, identifying 17 additional Italian melanoma cases (mostly from Genoa) and a single control, and subsequently confirmed all carriers of rs755147810 harbored the deletion. We verified cosegregation of the deletion in all available cases from four additional families (3/3, 2/2, 2/2 and 2/2 cases). The association of the MTAP variant with melanoma risk was highly significant when considering unrelated individuals from Italy, Spain, and Greece (3,219 cases and 2,266 controls; P = 4.34 x 10 -4 ; OR = 13.88) as well as Italian samples alone (2,170 cases, 1,888 controls; P = 4.14 x 10 -4 ; OR = 14.01). Analysis of a shared haplotype among carriers suggests a founder haplotype with the most recent common ancestor (MRCA) dating approximately 26 generations, i.e. the 17 th century, when Italy was repeatedly struck by devastating outbreaks of plague that profoundly affected major urban and commercial centers. The coincidence of the estimated MRCA timeframe with this major population collapse suggests that the demographic effects of the plague epidemic may have contributed to the persistence of this genetic variant in modern populations.In conclusion, our study provides evidence of a distant high-penetrance non-coding variant conferring melanoma susceptibility, with potential translational impact on facilitating screening and early-detection efforts in high-risk individuals.
利益披露 Disclosure
L. T. Bui-Raborn, None.. L. Pastorino, None.. D. Calista, None.. H. Hoang, None.. B. Dalmasso, None.. J. Scales, None.. S. Papiernik, None.. X. Wang, None.. R. Thakur, None.. S. Pellegrini, None.. M. Xu, None.. J. Yon, None.. W. Bruno, None.. T. Zhang, None.. Z. García-Casado, None.. E. Teresa Tanda, None.. F. Spagnolo, None.. M. Di Prete, None.. I. Bottillo, None.. S. Manukian, None.. M. Chiara Scaini, None.. K. P. Kypreou, None.. L. Di Nardo, None.. M. Potrony, None.. P. Aguilera-Peiró, None.. N. Shahrour, None.. T. Tran, None.. W. Zhou, None.. W. Lou, None.. A. L. Vogt, None.. J. Liu, None.. K. Jones, None.. M. Rodolfo, None.. I. Stefanaki, None.. C. Pellegrini, None.. C. Cota, None.. C. Menin, None.. M. Concetta Fargnoli, None.. K. Peris, None.. S. Puig, None.. E. Nagore, None.. P. Grammatico, None.. J. Shi, None.. P. Ghiorzo, None.. K. M. Brown, None.. M. Landi, None.

在会议检索中打开